VDPHL01 12-Month Results: Twice-Daily Dose Reaches +43.9 Hairs/cm² in Study ‘302’, No New Safety Signals
On November 9, 2026, Veradermics (NYSE: MANE) reported 12-month results from Part B of Study ‘302’, the Phase 2/3 trial […]
News
News
News
VDPHL01 Phase 3 Study ‘304’ Results: Confirmatory Trial Meets Every Endpoint — +36.4 Hairs/cm², No Cardiac Signal
On October 19, 2026, Veradermics (NYSE: MANE) announced positive topline results from Study ‘304’ — the confirmatory Phase 3 trial
News
VDPHL01 Mid-Year Update: Women’s Trial Fully Enrolled, $820M Runway Into 2030, First AAD Presentation
Veradermics’ second-quarter 2026 report (August 11, 2026) delivered three pieces of news that matter for anyone tracking VDPHL01 — the
News
VDPHL01 Meets Primary Endpoint in Women: Positive Phase 2 Results from Study ‘207’
Veradermics, Incorporated (NYSE: MANE) has reported positive topline results from the female treatment arms of Study ‘207’, an open-label Phase
News
Study 304, Study 306, and the FDA Path: What’s Next for VDPHL01
Update (October 19, 2026): The first milestone on this roadmap is done. Study ‘304’ met every primary and secondary endpoint
News
VDPHL01 Phase 2/3 Trial Results: Early, Robust Hair Growth — and a Clean Safety Record
Update (October 19, 2026): Confirmatory Phase 3 Study ‘304’ has now read out positive as well — +28.6 / +36.4